Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
2025

Targeting Replication Stress in Desmoplastic Small Round Cell Tumors

Sample size: 29 publication 10 minutes Evidence: high

Author Information

Author(s): A. Kawai-Kawachi, M.M. Lenormand, C. Astier, N. Herbel, M.B. Cutrona, C. Ngo, M. Garrido, T. Eychenne, N. Dorvault, L. Bordelet, F. Song, R. Bouyakoub, A. Loktev, A. Romo-Morales, C. Henon, L. Colmet-Daage, J. Vibert, M. Drac, R. Brough, E. Schwob, O. Martella, G. Pinna, J.M. Shipley, S. Mittnacht, A. Zimmermann, A. Gulati, O. Mir, A. Le Cesne, M. Faron, C. Honoré, C.J. Lord, R.M. Chabanon, S. Postel-Vinay

Primary Institution: Gustave Roussy, Villejuif, France

Hypothesis

Can targeting replication stress improve treatment outcomes in desmoplastic small round cell tumors (DSRCT)?

Conclusion

The study found that DSRCT cells are sensitive to PARP and ATR inhibitors, suggesting these drugs could be effective treatments for this aggressive cancer.

Supporting Evidence

  • EWS–WT1, the unique oncogenic driver of desmoplastic small round cell tumors, confers sensitivity to PARP and ATR inhibitors.
  • DSRCT cells showed increased DNA damage and replication stress when treated with PARP and ATR inhibitors.
  • The combination of PARP and ATR inhibitors induced a type I IFN response in DSRCT cells.

Takeaway

Researchers discovered that a type of cancer called DSRCT can be treated with specific drugs that target problems in how the cancer cells copy their DNA.

Methodology

The study involved high-throughput drug sensitivity screening in DSRCT cell lines and various preclinical models to assess the effectiveness of PARP and ATR inhibitors.

Potential Biases

Potential bias due to the limited number of models and the focus on specific drug classes.

Limitations

The study was limited by the availability of models for DSRCT, which is a rare disease, and the variability in PARP1 expression among different models.

Participant Demographics

The study primarily involved male patients with DSRCT, including a pediatric population.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1158/0008-5472.CAN-23-3603

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication